Editore: LAP LAMBERT Academic Publishing Jan 2017, 2017
ISBN 10: 3659907464 ISBN 13: 9783659907463
Lingua: Inglese
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 35,90
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware -Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill about two million people, mainly children, each year. Several new drugs along with chloroquine, the first synthetically developed antimalarial drug proved to be a successful cure in the past 50 years. The emergence and spread of resistant parasites to some of the drugs and their combination has made it virtually ineffective in most parts of the world. Few newer drugs like lumefantrine, Maloprim, Primaquine retain efficacy, have limitations and have a high cost. And thus, it is indispensable to discover, design, and develop new drugs with different mechanisms, with diversity in chemical structure and be efficacious against drug resistant strain. In addition to this it should be safe for small children and pregnant women, and be affordable. There are several targets validated for development of antimalarial agents. Falcipain-2 is a cysteine protease enzyme, a validated target for malaria. Several studies confirmed the efficacy of cysteine protease inhibitors in arresting and killing parasites in tissue culture models of parasite replication or cell invasion.Books on Demand GmbH, Überseering 33, 22297 Hamburg 84 pp. Englisch.
Editore: LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3659907464 ISBN 13: 9783659907463
Lingua: Inglese
Da: Revaluation Books, Exeter, Regno Unito
EUR 60,96
Convertire valutaQuantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 84 pages. 8.66x5.91x0.19 inches. In Stock.
Editore: LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3659907464 ISBN 13: 9783659907463
Lingua: Inglese
Da: moluna, Greven, Germania
EUR 31,27
Convertire valutaQuantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Patel Kuldeep SinghMr.Kuldeep Patel,M.Pharm,B.Pharm is an Associate Professor in NRI Institute of Pharmaceutical Science,Bhopal,India. He is pursuing Ph.d from AIP, Amity University NOIDA, U.P. He has 7 years teaching experience. He .
Editore: LAP LAMBERT Academic Publishing Jan 2017, 2017
ISBN 10: 3659907464 ISBN 13: 9783659907463
Lingua: Inglese
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 35,90
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill about two million people, mainly children, each year. Several new drugs along with chloroquine, the first synthetically developed antimalarial drug proved to be a successful cure in the past 50 years. The emergence and spread of resistant parasites to some of the drugs and their combination has made it virtually ineffective in most parts of the world. Few newer drugs like lumefantrine, Maloprim, Primaquine retain efficacy, have limitations and have a high cost. And thus, it is indispensable to discover, design, and develop new drugs with different mechanisms, with diversity in chemical structure and be efficacious against drug resistant strain. In addition to this it should be safe for small children and pregnant women, and be affordable. There are several targets validated for development of antimalarial agents. Falcipain-2 is a cysteine protease enzyme, a validated target for malaria. Several studies confirmed the efficacy of cysteine protease inhibitors in arresting and killing parasites in tissue culture models of parasite replication or cell invasion. 84 pp. Englisch.
Editore: LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3659907464 ISBN 13: 9783659907463
Lingua: Inglese
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 35,90
Convertire valutaQuantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill about two million people, mainly children, each year. Several new drugs along with chloroquine, the first synthetically developed antimalarial drug proved to be a successful cure in the past 50 years. The emergence and spread of resistant parasites to some of the drugs and their combination has made it virtually ineffective in most parts of the world. Few newer drugs like lumefantrine, Maloprim, Primaquine retain efficacy, have limitations and have a high cost. And thus, it is indispensable to discover, design, and develop new drugs with different mechanisms, with diversity in chemical structure and be efficacious against drug resistant strain. In addition to this it should be safe for small children and pregnant women, and be affordable. There are several targets validated for development of antimalarial agents. Falcipain-2 is a cysteine protease enzyme, a validated target for malaria. Several studies confirmed the efficacy of cysteine protease inhibitors in arresting and killing parasites in tissue culture models of parasite replication or cell invasion.